News & Updates

Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.

Individuals with type 2 diabetes (T2D) who regularly consume ultraprocessed foods (UPF), regardless of diet quality, appear to have reduced survival and increased cardiovascular disease (CVD) mortality rate, suggests a recent study.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in significant weight loss in patients with obesity or overweight without diabetes, a study has shown. In addition, the best GLP-1RA agent appears to be semaglutide, showing superior efficacy and low-to-moderate risk of side effects.

Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.

Treatment with electrofulguration for antibiotic-refractory recurrent urinary tract infections (UTI) demonstrates durable clinical cure and improvement over 5 years in menopausal women, reducing the need for long-term antibiotics, a study has shown.

Type 1 diabetes (T1D) is significantly associated with the risk of sexual dysfunction among women, according to the results of a systematic review and meta-analysis.